Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Eosinophilic Chronic Rhinosinusitis
NCT02772419Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jun 2016
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of benralizumab in eosinophilic chronic rhinosinusitis (ECRS) (3 arms), sponsored by Kyowa Kirin. Primary endpoint: Change from baseline in nasal polyp score at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic chronic rhinosinusitis (ECRS)
Beyond the preview
Go deeper on NCT02772419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772419.